$2 Trillion Disappears Because of Fed's Secretive New Move

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Robert J. Shovlin net worth and biography

Robert Shovlin Biography and Net Worth

Insider of NeoGenomics

Mr. Shovlin joined NeoGenomics in 2014 as the Chief Operating Officer, and now serves as the President, Clinical Services Division. Previously, he served as Chief Development Officer for Bostwick Laboratories, a leading provider of anatomic pathology testing services. From 2005 to 2011, he served in several positions of increasing responsibility, ultimately as President and Chief Executive Officer for Aureon Biosciences, Inc., a venture-backed diagnostics company focused on developing novel and proprietary prostate cancer tests. Mr. Shovlin also served as Executive Director of Anatomic Pathology and as Director of Managed Care for Quest Diagnostics from 2003 until 2005, and held sales leadership positions at Dianon Systems from 1997 until 2003. Mr. Shovlin served as a Captain, Infantry Officer, in the United States Marine Corps from 1992 until 1997 where he served as a Platoon Commander and Company Commander with 1st Battalion 4th Marines and as an Instructor and Staff Platoon Commander at The Basic School. He received his bachelor’s degree from Pennsylvania State University, and his MBA in Finance from Rutgers University.

What is Robert J. Shovlin's net worth?: The estimated net worth of Robert J. Shovlin is at least $4.29 million as of May 25th, 2021. Mr. Shovlin owns 249,914 shares of NeoGenomics stock worth more than $4,286,025 as of December 25th. This net worth evaluation does not reflect any other assets that Mr. Shovlin may own. Learn More about Robert J. Shovlin's net worth.
How do I contact Robert J. Shovlin?: The corporate mailing address for Mr. Shovlin and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on Robert J. Shovlin's contact information.
Has Robert J. Shovlin been buying or selling shares of NeoGenomics?: Robert J. Shovlin has not been actively trading shares of NeoGenomics over the course of the past ninety days. Most recently, Robert J. Shovlin sold 130,604 shares of the business's stock in a transaction on Tuesday, May 25th. The shares were sold at an average price of $39.31, for a transaction totalling $5,134,043.24. Following the completion of the sale, the insider now directly owns 249,914 shares of the company's stock, valued at $9,824,119.34. Learn More on Robert J. Shovlin's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), and Robert Shovlin (Insider). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 7,762 shares worth more than $118,189.52. The most recent insider tranaction occured on November, 15th when General Counsel Alicia C Olivo sold 5,175 shares worth more than $79,488.00. Insiders at NeoGenomics own 1.3% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 11/15/2024.

Robert J. Shovlin Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/25/2021	Sell	130,604	$39.31	$5,134,043.24	249,914
7/30/2020	Sell	81,356	$38.17	$3,105,358.52	212,902
3/4/2020	Sell	98,093	$30.86	$3,027,149.98	249,733
10/31/2019	Sell	70,473	$23.11	$1,628,631.03	251,914
2/27/2019	Sell	186,014	$18.96	$3,526,825.44	40,166
11/12/2018	Sell	216,493	$17.00	$3,680,381.00	339,884
11/9/2018	Sell	180,000	$17.05	$3,069,000.00	339,884
6/29/2018	Sell	12,941	$13.12	$169,785.92	39,884
12/3/2015	Buy	6,550	$7.75	$50,762.50	6,550

Robert J. Shovlin Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $17.15

$16.29

$17.17

50 Day Range

MA: $15.80

$13.05

$18.43

2 Week Range

Now: $17.15

$12.77

$20.94

Volume

469,000 shs

Average Volume

805,794 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

Click here to see his new research now.